ENGN

In September 2026, the company reported its Third Quarter 2026 Financial Results, provided a business update, and announced participation in upcoming investor conferences. In August 2026, enGene hosted a virtual Key Opinion Leader (KOL) event to discuss emerging Non-Muscle Invasive Bladder Cancer (NMIBC) market insights. In July 2026, the company focused its Board to support planned upcoming regulatory and commercial milestones. In June 2026, enGene announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates, including plans for 12-month complete response data from the LEGEND pivotal cohort and subsequent FDA engagement in the second half of 2026, as well as the initiation of a Biologics License Application (BLA) filing for detalimogene in the same period. The company also reported enrolling the first patients in a surfactant plus detalimogene cohort and implemented a significant reduction in force (approximately 50%) to streamline operations and preserve cash, focusing on BLA and precommercial activities, while being well-capitalized with $285 million in cash, cash equivalents, and marketable securities. In April 2026, the company changed its corporate name from enGene Holdings Inc. to enGene Therapeutics Inc., effective April 8, 2026, to reflect its near-term transition towards becoming a potential commercial organization with the anticipated approval of detalimogene voraplasmid in 2027, with its common shares continuing to trade under the ticker 'ENGN' on Nasdaq.